Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 3 (TRuE-AD3)

Brief description of study

Atopic dermatitis (AD), also called eczema, is a skin condition that makes your child’s skin red, scaly, and very itchy. AD is long-lasting and can flare or worsen from time to time. Children with AD may also be more likely to develop asthma and/or food allergies. Currently, there are a number of treatments available for AD, but there is still a need for safe topical treatments that provide fast and effective control of the symptoms of AD, particularly in children. The purpose of this Research Study, is to determine if an investigational cream, ruxolitinib cream, is safe and effective to treat AD. In this Study, ruxolitinib cream will be compared to a “vehicle cream” for the first 8 weeks. The vehicle cream looks like the ruxolitinib cream but contains no ruxolitinib. When ruxolitinib cream is mentioned together with the vehicle cream, they will collectively be called the “Study Cream.” After 8 weeks, your child will be treated only with ruxolitinib cream for 44 weeks, a period called long-term safety.


Clinical Study Identifier: s21-00745
ClinicalTrials.gov Identifier: NCT04921969
Principal Investigator: Kanwaljit Brar.
Other Investigator: Anna H Nowak-Wegrzyn.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.